MA06.05 Consolidation Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation for Patients with Unresectable Stage III NSCLC by Durm, G.A., Mamdani, H., Althouse, S., Jabbour, S., Ganti, A., Jalal, S., Chesney, J., Naidoo, J., Hrinczenko, B., Fidler, M.J., Leal, T., Feldman, L., Fujioka, N., Hanna, N.

Get full text

OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC by Li, B.T., Falchook, G.S., Durm, G.A., Burns, T.F., Skoulidis, F., Ramalingam, S.S., Spira, A., Bestvina, C.M., Goldberg, S.B., Veluswamy, R., Iams, W.T., Chiappori, A.A., Lemech, C.R., Meloni, A.R., Ebiana, V., Dai, T., Gauto, D.M., Varrieur, T.L., Snyder, W.J., Govindan, R.

Get full text

EP14.05-004 Temozolomide and Atezolizumab as Second Line Treatment for Extensive Stage Small Cell Lung Cancer: A Randomized, Multi-Cohort Phase 2 Trial by Owen, D.H., Durm, G.A., Wei, L., Pilcher, C., Ferguson, S., Benner, B., Jukich, M., Sukrithan, V., Konda, B., Savardekar, H., Spakowicz, D., Schwarz, E., Norman, R.O., Wesolowski, R., Carson, W.E., Kaufman, J., Alahmadi, A., Memmott, R., Shields, P., He, K., Bertino, E.M., Presley, C.J., Carbone, D.P., Otterson, G.A.

Get full text

OA02.03 Potential Predictors of Pembrolizumab Associated Pneumonitis: A Retrospective Review of the HCRN LUN 14-179 Trial: Topic: Medical Oncology by Ahmed, S.S., Durm, G.A., Donatelli, J., Liu, Y., Yao, H., Desrosiers, C., Liu, Z., Kong, F.M., Hanna, N.

Get full text

OA02.03 Potential Predictors of Pembrolizumab Associated Pneumonitis: A Retrospective Review of the HCRN LUN 14-179 Trial by Ahmed, S.S., Durm, G.A., Donatelli, J., Liu, Y., Yao, H., Desrosiers, C., Liu, Z., Kong, F.M., Hanna, N.

Get full text